Savara Provides Regulatory Update on MOLBREEVI Development Program for Autoimmune Pulmonary Alveolar Proteinosis
Savara clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, has announced a significant regulatory update regarding its investigational therapy MOLBREEVI, which is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (autoimmune PAP). The company revealed that it has received the Day 74 Letter from the U.S. Food and Drug Administration (FDA) related to its Biologics License Application (BLA) for MOLBREEVI, marking an important milestone in the ongoing regulatory review process.
According to the update, the Day 74 Letter from the FDA indicated that the agency currently has no plans to convene an advisory committee meeting for the MOLBREEVI application. The absence of an advisory committee meeting is often viewed as a positive development in the regulatory review process, suggesting that the FDA may not require additional external expert consultation before making a decision. The application remains under active review, and the FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026, for its final decision on the therapy.
Ongoing Regulatory Review in the United States
The submission of the Biologics License Application represents a critical step in Savara’s efforts to bring MOLBREEVI to patients suffering from autoimmune PAP, a rare and potentially debilitating lung disease. If approved, MOLBREEVI could become the first therapy specifically authorized to treat this condition in the United States.
The PDUFA target action date established by the FDA marks the timeline by which the agency aims to complete its review and issue a regulatory decision. During this review period, the FDA evaluates data from clinical studies, manufacturing processes, safety and efficacy results, and other relevant information to determine whether the treatment meets the standards required for approval.
Savara’s announcement that an advisory committee meeting is not currently planned suggests that the FDA may be satisfied with the data submitted in the application, although the agency retains the right to schedule such a meeting later if additional input is required. For biotechnology companies developing therapies for rare diseases, reaching this stage of regulatory review represents a significant achievement.
Progress Toward European Approval
In addition to its ongoing regulatory process in the United States, Savara has also made progress toward obtaining approval in Europe. The company recently submitted a Marketing Authorization Application (MAA) for MOLBREEVI to the European Medicines Agency (EMA). This submission initiates the formal review process that could potentially lead to approval across the European Union.
The EMA plays a central role in evaluating medicines intended for use in the EU. Once an MAA is submitted, the agency conducts a comprehensive scientific assessment to determine whether the therapy’s benefits outweigh its risks. If the EMA recommends approval, the European Commission can grant marketing authorization that allows the therapy to be marketed throughout EU member states.
Savara’s submission to the EMA signals the company’s commitment to expanding access to MOLBREEVI for patients beyond the United States. Because autoimmune PAP is a rare disease with limited treatment options worldwide, regulatory approvals in multiple regions could significantly impact patient care.
Planned Submission in the United Kingdom
The company also announced that it is preparing to submit an additional Marketing Authorization Application to the United Kingdom’s regulatory authority, the Medicines and Healthcare Products Regulatory Agency (MHRA). According to Savara, the submission to the MHRA remains on track and is expected to occur by the end of the first quarter of 2026.
The MHRA oversees the regulation of medicines and medical devices in the United Kingdom and conducts independent assessments to ensure that therapies meet safety, quality, and efficacy standards. Following the UK’s departure from the European Union, pharmaceutical companies must submit separate applications to the MHRA to secure approval for use in the UK market.
By pursuing regulatory review in the United States, Europe, and the United Kingdom simultaneously, Savara aims to make MOLBREEVI accessible to patients across multiple major healthcare markets.
Addressing an Unmet Medical Need
Autoimmune pulmonary alveolar proteinosis is a rare lung disorder characterized by the accumulation of surfactant—a substance that helps keep air sacs open—within the alveoli of the lungs. This buildup interferes with normal gas exchange, leading to breathing difficulties and reduced oxygen levels in the blood.
Patients with autoimmune PAP often experience symptoms such as shortness of breath, chronic cough, fatigue, and reduced exercise tolerance. In severe cases, the disease can significantly impair lung function and quality of life. Currently, treatment options are limited and may include procedures such as whole-lung lavage, which involves washing out the lungs to remove accumulated material.
Savara is developing MOLBREEVI as a targeted therapy designed to address the underlying biological mechanisms associated with autoimmune PAP. If successful, the therapy could offer patients a less invasive and more effective treatment option compared to existing management approaches.
Leadership Perspective on the Development Program
Matt Pauls, Chair and Chief Executive Officer of Savara, expressed optimism about the progress of the MOLBREEVI development program and the potential impact of the therapy on patients with autoimmune PAP.
According to Pauls, MOLBREEVI has the potential to become a first-in-class treatment for this rare lung disease, which currently lacks approved therapies in both the United States and Europe. He emphasized the company’s confidence in the therapy’s ability to address the significant unmet needs of patients living with autoimmune PAP.
Pauls also noted that Savara looks forward to continued collaboration with global regulatory agencies during the review process. Working closely with authorities such as the FDA and the EMA will be essential as the company seeks to bring MOLBREEVI to market and provide new treatment options for patients affected by the condition.
Special Regulatory Designations
MOLBREEVI has received several regulatory designations from major health authorities, reflecting both the rarity of autoimmune PAP and the potential importance of the therapy.
The FDA has granted MOLBREEVI both Fast Track and Breakthrough Therapy Designations for the treatment of autoimmune PAP. Fast Track designation is intended to facilitate the development and review of drugs that address serious conditions and fill unmet medical needs, while Breakthrough Therapy designation is granted to treatments that show substantial improvement over existing therapies based on preliminary clinical evidence.
In addition, MOLBREEVI has received Orphan Drug Designation from both the FDA and the EMA. Orphan Drug status is provided to therapies intended to treat rare diseases and offers several incentives to developers, including market exclusivity, tax credits, and assistance during the regulatory process.
The therapy has also received Innovation Passport (IP) and Promising Innovative Medicine (PIM) designations from the UK’s MHRA. These designations are designed to support the development of innovative medicines and may enable faster patient access if the therapy demonstrates significant clinical benefits.
Forward-Looking Statements and Potential Risks
Savara cautioned that certain statements included in the announcement constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to expectations about future events, regulatory decisions, development timelines, and the potential clinical benefits of MOLBREEVI.
Forward-looking statements often include language referencing future plans or expectations, such as “anticipate,” “believe,” “expect,” “intend,” or “will.” While these statements reflect the company’s current outlook, they involve assumptions and uncertainties that could cause actual results to differ from those predicted.
Several factors could affect the eventual outcome of the MOLBREEVI development program. These include the company’s ability to successfully complete clinical development, obtain regulatory approvals, and commercialize the therapy if approved. Changes in regulatory requirements, financial constraints, and challenges in raising additional capital may also impact the program’s progress.
Savara emphasized that investors and stakeholders should not place undue reliance on forward-looking statements, as these statements are based on current expectations and may change as new information becomes available.
Looking Ahead
As the regulatory review of MOLBREEVI continues, Savara remains focused on advancing the therapy through the approval process and preparing for potential commercialization. With submissions underway in the United States and Europe and additional filings planned in the United Kingdom, the company is positioning itself to address the unmet needs of patients with autoimmune PAP on a global scale.
If approved, MOLBREEVI could represent a major advancement in the treatment of this rare lung disease, potentially offering patients a targeted therapy designed to improve lung function and overall quality of life. Over the coming months, the progress of regulatory reviews and the FDA’s decision expected in August 2026 will be closely watched by the medical community, patients, and industry stakeholders alike.
About Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent them from collapsing. In a healthy lung, excess surfactant is cleared and digested by immune cells called alveolar macrophages. Alveolar macrophages need to be stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF) to function properly in clearing surfactant, but in autoimmune PAP, GM-CSF is neutralized by antibodies against GM-CSF, rendering macrophages unable to adequately clear surfactant. As a result, an excess of surfactant accumulates in the alveoli, causing impaired gas exchange, resulting in clinical symptoms of shortness of breath, often with cough and frequent fatigue. Patients may also experience episodes of fever, chest pain, or coughing up blood, especially if secondary lung infection develops. In the long term, the disease can lead to serious complications, including lung fibrosis and the need for a lung transplant.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI* is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization
